{"log_id": 67580905826451876, "direction": 0, "words_result_num": 21, "words_result": [{"probability": {"variance": 0.000347, "average": 0.986785, "min": 0.960434}, "location": {"width": 27, "top": 76, "height": 109, "left": 1129}, "words": "约批件"}, {"probability": {"variance": 6e-06, "average": 0.998327, "min": 0.990826}, "location": {"width": 806, "top": 231, "height": 30, "left": 213}, "words": "一项小型随机、双盲、阳性对照研究中,在患有失代偿肝病的慢性乙肝受试者中评价"}, {"probability": {"variance": 0.000141, "average": 0.995029, "min": 0.94473}, "location": {"width": 724, "top": 263, "height": 30, "left": 211}, "words": "富马酸替诺福韦二吡呋酯48周治疗相对其他抗病毒药物安全性(研究0108)"}, {"probability": {"variance": 6.9e-05, "average": 0.996354, "min": 0.958264}, "location": {"width": 800, "top": 315, "height": 29, "left": 215}, "words": "45名成人受试者(男37名,女8名)随机纳入富马酸替诺福韦二吡呋酯治疗组。基"}, {"probability": {"variance": 0.000929, "average": 0.985841, "min": 0.837991}, "location": {"width": 802, "top": 346, "height": 28, "left": 212}, "words": "线时,69%受试者 Hbeag呈阴性,31% Hbeag呈阳性。受试者基线时 Child-Pugh评分"}, {"probability": {"variance": 0.005689, "average": 0.965466, "min": 0.714687}, "location": {"width": 811, "top": 376, "height": 27, "left": 211}, "words": "均值为7,MELD评分均值为12, HBV DNA均值为5.81og1拷贝/毫升,ALT均值为"}, {"probability": {"variance": 0.00087, "average": 0.991851, "min": 0.816144}, "location": {"width": 819, "top": 406, "height": 27, "left": 211}, "words": "61U/L。试验终点为因不良事件中止治疗和经确认的血清肌酐增加≥0.5mg/dL,或"}, {"probability": {"variance": 0.00081, "average": 0.986152, "min": 0.912182}, "location": {"width": 453, "top": 433, "height": 31, "left": 211}, "words": "确认血清无机磷<2mg/dL。(参见不良反应)"}, {"probability": {"variance": 4.2e-05, "average": 0.996089, "min": 0.968812}, "location": {"width": 774, "top": 486, "height": 27, "left": 212}, "words": "截至第48周时,富马酸替诺福韦二吡呋酯治疗组中分别有31/44(70%)和12/26"}, {"probability": {"variance": 9e-05, "average": 0.994804, "min": 0.957335}, "location": {"width": 795, "top": 516, "height": 27, "left": 222}, "words": "(46%)例受试者达 HBV DNA<400拷贝/毫升和ALT复常。试验设计不包括评价治疗"}, {"probability": {"variance": 2.4e-05, "average": 0.997686, "min": 0.978776}, "location": {"width": 500, "top": 545, "height": 28, "left": 212}, "words": "对临床终点的影响,如肝病进展、肝移植需求或死亡"}, {"probability": {"variance": 2e-06, "average": 0.999157, "min": 0.99531}, "location": {"width": 221, "top": 596, "height": 27, "left": 211}, "words": "中国慢性乙肝感染患者"}, {"probability": {"variance": 0.003921, "average": 0.97679, "min": 0.632329}, "location": {"width": 805, "top": 648, "height": 28, "left": 211}, "words": "研究LOC114648是一项随机、双盲、阳性对照3期研究,评价富马酸替诺福韦三吡呋"}, {"probability": {"variance": 0.000722, "average": 0.993816, "min": 0.826837}, "location": {"width": 838, "top": 678, "height": 29, "left": 210}, "words": "酯300mg与阿德福韦酯10mg在509名中国 Hbeag I阳性或阴性代偿性慢性乙肝受试者"}, {"probability": {"variance": 0.000108, "average": 0.994939, "min": 0.939581}, "location": {"width": 867, "top": 706, "height": 36, "left": 211}, "words": "中的疗效和安全性。患者平均年龄36岁,83%男性,40% Hbeag阳性,95%核苷(酸)初"}, {"probability": {"variance": 0.012517, "average": 0.947136, "min": 0.507085}, "location": {"width": 861, "top": 734, "height": 39, "left": 209}, "words": "治者。基线时, Hbeag阳性患者血浆 HBV DNA I两治疗组均为8.71og拷贝毫升,A血"}, {"probability": {"variance": 0.002802, "average": 0.984049, "min": 0.663958}, "location": {"width": 891, "top": 759, "height": 55, "left": 209}, "words": "清ALT平均值富马酸替诺福韦二吡呋酯组199U/L,阿德福韦酯组189U/L。基线时,Q"}, {"probability": {"variance": 0.010197, "average": 0.952693, "min": 0.596029}, "location": {"width": 843, "top": 793, "height": 34, "left": 210}, "words": "HeAg阴性患者血浆 HBV DNA均值富马酸替诺福韦二吡呋酯组6.91og拷贝/毫升,平"}, {"probability": {"variance": 0.004935, "average": 0.973833, "min": 0.655418}, "location": {"width": 827, "top": 824, "height": 28, "left": 210}, "words": "阿德福韦酯组7.01og1拷贝/毫升,血清ALT平均值富马酸替诺福韦二吡呋酯组133"}, {"probability": {"variance": 4.1e-05, "average": 0.996343, "min": 0.973719}, "location": {"width": 252, "top": 853, "height": 26, "left": 209}, "words": "U/L,阿德福韦酯113U/L"}, {"probability": {"variance": 1.9e-05, "average": 0.997659, "min": 0.981071}, "location": {"width": 659, "top": 904, "height": 29, "left": 212}, "words": "所有患者完成48周治疗后进行主要数据分析,结果总结如下(表13)"}], "language": 3}